Targeting the indoleamine 2,3-dioxygenase pathway in cancer - sprookjes - yvandenbroek - TriplyDB

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

http://www.wikidata.org/entity/Q26775471

about

Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?Inflammation Models of Depression in Rodents: Relevance to Psychotropic Drug Discovery Molecular basis for catalysis and substrate-mediated cellular stabilization of human tryptophan 2,3-dioxygenase IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment.Expression and Prognostic Value of Indoleamine 2,3-dioxygenase in Pancreatic Cancer.Strong Correlation of Indoleamine 2,3-Dioxygenase 1 Expression with Basal-Like Phenotype and Increased Lymphocytic Infiltration in Triple-Negative Breast Cancer.Binding properties of different categories of IDO1 inhibitors: a microscale thermophoresis study.Assessment of Tryptophan Uptake and Kinetics Using 1-(2-18F-Fluoroethyl)-l-Tryptophan and α-11C-Methyl-l-Tryptophan PET Imaging in Mice Implanted with Patient-Derived Brain Tumor Xenografts.Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions.Chromatographic analysis of tryptophan metabolites.Mesenchymal Stem Cells in Myeloid Malignancies: A Focus on Immune Escaping and Therapeutic Implications.EWS-FLI1 impairs aryl hydrocarbon receptor activation by blocking tryptophan breakdown via the kynurenine pathway.Update on squamous cell carcinoma of the head and neck: ASCO annual meeting 2017.Cancer immunotherapy beyond immune checkpoint inhibitors.Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA.Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model.Targeting CTLA-4, PD-L1 and IDO to modulate immune responses in vitiligo.Metabolic Footprints and Molecular Subtypes in Breast Cancer.The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective.Amino Acid Catabolism in Multiple Sclerosis Affects Immune Homeostasis.Updates on immunotherapy for colorectal cancer.Next generation of immune checkpoint therapy in cancer: new developments and challenges.High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma.Overview of Basic Immunology for Clinical Investigators.Clinical Development of PD-1 in Advanced Melanoma.Immuno-oncology in urothelial carcinoma: who or what will ultimately sit on the iron throne?β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.Mechanisms of Intrinsic Tumor Resistance to Immunotherapy.High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer.Advanced non-small cell lung cancer: the role of PD-L1 inhibitors.1-Methyl-D-tryptophan Reduces Tumor CD133+ cells, Wnt/β-catenin and NF-κβp65 while Enhances Lymphocytes NF-κβ2, STAT3, and STAT4 Pathways in Murine Pancreatic Adenocarcinoma.Immuno-Oncology: Emerging Targets and Combination Therapies The Application of Nanoparticle-Based Drug Delivery Systems in Checkpoint Blockade Cancer Immunotherapy The Tumor Vascular Endothelium as Decision Maker in Cancer Therapy The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets Next Generation Cancer Vaccines-Make It Personal!

P2860

Q26738359-A76753C4-F43E-4633-8629-573D938A52B4 Q26746104-49E0382A-261C-4FBB-8B35-9156CCFF3A41 Q26749497-7BD1907F-7ED1-49BB-A4FE-952B77051BEA Q28115713-2FF8AE00-10F6-4A08-BD17-B5A6C1B070D1 Q33849567-9BE837D3-4154-429E-879E-6DF6AF794309 Q37516448-561958C5-C897-4716-A668-25FD907B7FDD Q37711667-21F12544-2BB3-4537-B231-1400EC1AFC08 Q38406396-40C9536F-EB8B-415C-A4C0-28354F94257E Q38647699-E246206D-A11E-4687-BA3E-BFFC447688D9 Q38739230-6B538344-B752-4192-B96A-634E8F7DE52A Q38847861-72DA173C-B7D2-4365-A6DC-8E01A534D88E Q39356675-1F57C637-2D74-4659-B2D5-FDC2A21C9791 Q41695046-A332FA72-9735-40C1-B5C8-AFCB116FA265 Q42350421-DE6DA3BB-CD71-424A-92CE-0DAAE10351B1 Q47095527-174F1D08-0F0F-4DB3-BD92-09C4B273A96F Q47554248-D3345BA0-0C70-42E5-90D5-4DCBA622114B Q47936113-5737B58B-EB31-45F1-A0DD-DF1DFAD21789 Q48177244-2800466D-63E5-4A95-A321-9AD087A33680 Q48766890-111011A8-5AAC-46C6-ACA2-5865C2D9A8B6 Q49048342-A10F8F01-1941-406D-807F-F8A93DB6BB69 Q49871101-85AD54E2-B239-4675-B98B-3E01E63D23CA Q50033731-DE0853CC-B94D-4332-820C-01DAB00DF69D Q51165149-2F7D7C5F-0D4B-4909-BDBB-01C0539AEF28 Q52643529-41599784-B54D-49AA-84A5-E62C83DCB45C Q52653710-9A7568F7-19C8-4939-8318-97B9D28A075E Q52677218-9F7F91E2-43D2-4B51-9A63-8EDF1E81BF7F Q52699143-E6853418-DE78-4DDE-9E7A-7921B18E4279 Q52707889-D4957628-BD2E-4122-B238-8B0914974C8E Q52752658-23400EDA-ABED-404F-8B57-A3E136D15868 Q52801913-533BE681-BB63-4DE0-BB2D-5E96BB8BD084 Q53826191-5B9AA00F-F772-4FDC-83E4-7FDD420B4678 Q55224564-5E6A9FEE-EB02-4FBB-943C-C27A737FF225 Q55316781-9A70143D-5960-4352-B3AB-190049991C00 Q55516059-E36075DC-0E2F-4B01-812E-ACB3A389F604 Q56889817-C5721702-98B5-4143-B105-2594931AE9E1 Q58604249-F956B3EE-0109-4C06-A14A-752783ECA1AB Q58754484-D4C7D322-C654-45BF-AD33-C204E0895C68 Q58791203-30AA4706-8818-44A9-9548-3F541E642C33 Q58791982-9D8FBE08-A485-4CFA-BACD-8D3FA9AABDC4

P2860

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

http://www.wikidata.org/entity/Q26775471

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

@ast

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

@en

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

@nl

type

label

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

@ast

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

@en

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

@nl

prefLabel

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

@ast

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

@en

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

@nl

P1433

Q26775471-BD8FC390-7FE2-4958-8FBC-BF7C65C0EF62

P1476

Q26775471-A1D97758-BB03-4C04-861B-54404909ED1D

P2093

Q26775471-4200B59D-B445-4A50-94B5-3A0C2377AA33

Q26775471-A94B1571-BD44-47B8-85EA-446C69719253

Q26775471-CAC8DF09-4702-4B67-944F-36A24A19D646

P2860

Q26775471-06236589-A78D-4097-8762-60D5B7096A7F

Q26775471-078935E1-6153-4691-97D9-F0F05585C806

Q26775471-08484557-7240-4F46-9D3A-FE9666C2F748

Q26775471-0995825B-5289-46F5-B0CD-5F1061ED1EFA

Q26775471-0A8BF152-17AA-4ACE-A3DB-AA61DEF6C434

Q26775471-0C087F95-682E-4CDE-BFDD-C9B912FB56A5

Q26775471-0DF19EE7-CA66-4347-81D3-B95116265897

Q26775471-0F5F8044-CE3C-41BB-B515-1443BEDECABD

Q26775471-0FA709E3-1595-4E42-A93C-B0E65C03B840

Q26775471-1278873F-C5D7-448B-A319-4EF9B3F19A48

P2888

Q26775471-9376FA45-F947-49EC-8A42-8F1BC3DE1D36

P304

Q26775471-983F53F1-AF38-46B0-B935-0FBB8F7F0EAE

P31

Q26775471-A6C84E3E-964D-4314-BD87-EC9D56963BBD

P3181

Q26775471-F8A695C0-C241-4BC2-AE63-4E3CCBB655D8

P356

Q26775471-008D2631-7DBC-420D-9E00-2334501F140D

P407

Q26775471-68DA9092-DA99-4F1B-81E6-A97A533C6264

P433

Q26775471-84241DA1-1E47-425C-998E-FA80652E4CC8

P478

Q26775471-9A9281B6-FB50-48AF-99E0-6071F2410029

P50

Q26775471-80895032-67FE-47E3-821E-FBF1CC0EED7D

P577

Q26775471-61D780FA-9EF1-4BFE-9CB0-15956FF2E8DC

P5875

Q26775471-72855C05-2B84-42A3-8866-04AFAA2E8CC6

P6179

Q26775471-E5A940C3-CE54-4A5C-B0C0-C03B60DEB478

P698

Q26775471-91D464EC-4089-4BBD-B28D-2C2BD631944E

P932

Q26775471-A8614AAF-7C5F-46C5-B023-3F96B76600BC

P3181

P356

S40425-015-0094-9

P1433

Journal for Immunotherapy of Cancer

P1476

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

@en

P2093

Joud Hajjar

http://www.w3.org/2001/XMLSchema#string

Patrick Hwu

http://www.w3.org/2001/XMLSchema#string

Yong Wha Moon

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice

Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan

Prevention of allogeneic fetal rejection by tryptophan catabolism

The kinase GLK controls autoimmunity and NF-κB signaling by activating the kinase PKC-θ in T cells

The response of autologous T cells to a human melanoma is dominated by mutated neoantigens

Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response

Human tumor antigens recognized by T lymphocytes

Nivolumab plus ipilimumab in advanced melanoma.

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

P2888

s40425-015-0094-9

P304

51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2892837

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/S40425-015-0094-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283430834

http://www.w3.org/2001/XMLSchema#string

P6179

1022743938

http://www.w3.org/2001/XMLSchema#string

P698

26674411

http://www.w3.org/2001/XMLSchema#string

P932

4678703

http://www.w3.org/2001/XMLSchema#string